Details

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region.

The EASL Recommendations on Treatment of Hepatitis C Webinar is intended to assist physicians and other healthcare providers, in the clinical decision-making process, by describing the current optimal management of patients with recently acquired and chronic HCV infections.

Access the 2020 EASL Recommendations on Treatment of Hepatitis C publication. 

Join us on 26 January 2021 at 18:00 CET for this live webinar. Register now


Targeted Audience

  • Hepatologists
  • Health care professionals
  • General HCV-treatment practitioners

Learning Objectives

  • Understand how to treat HCV infection in 2021 and beyond
  • Learn how to use simplified HCV therapy to improve access to care
  • Learn about new recommendations on special groups and comorbidities
  • Understand how to handle patients with DAA treatment failures
  • Apprehend how to implement simple treatment rules to achieve HCV elimination goals

Programme

Time Title
18:00-18:15

Presentation of the new EASL Recommendations

Jean-Michel Pawlotsky

18:15-18:20

Extra-hepatic manifestations

Francesco Negro

18:20-18:25

Children and pregnant women

Fiona Marra

18:25-18:30

PWID and prisoners

Olav Dalgard

18:30-18:35

Organ (including liver) transplant setting

Marina Berenguer

18:35-18:40

Hepatocellular carcinoma

Geoffrey Dusheiko

18:40-18:45

Recently acquired hepatitis C

Heiner Wedemeyer

18:45-18:50

Treatment failures and retreatment

Alessio Aghemo

18:50-18:55

Reinfections

Massimo Puoti

18:55-19:30

Q&A session

Marina Berenguer

Geoffrey Dusheiko

Jean-Michel Pawlotsky

Thomas Berg

Live Webinar Faculty

Thomas Berg

Thomas Berg is the Head of the Department of Hepatology, Department of Medicine II, University Hospital Leipzig, Germany. He also serves as the Vice-Secretary General of EASL. His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials.

Jean-Michel Pawlotsky

Jean-Michel Pawlotsky is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and Director of research team “Viruses-Hepatology-Cancers“ at the Mondor Institute of Biomedical Research (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology.

Marina Berenguer

Marina Berenguer is an Associate Professor of Medicine at the University of Valencia. Recognized in the field of Hepatology and Liver Transplantation, particularly in hepatitis C. Research Coordinator within a National Network Research Center in Hepatology, Ciber-ehd. Associate editor in “Liver Transpl” and “J Hepatol” from 2010 to 2014 and Deputy Editor in “Transplantation” (2015-2020) and J Hepatol Reports (2019-2022). Co-founder in 2016 of the Spanish Group of Women Hepatologists (GEMHEP). ILTS (International Society of Liver Transplantation) President-elect.

Geoffrey Dusheiko

Geoffrey Dusheiko is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and a consultant Hepatologist at King's College Hospital in London. Professor Dusheiko's research expertise includes the management and treatment of HCV, HBV, and small hepatocellular carcinoma. Within viral hepatitis, his special interests lie in viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis, and antiviral therapies.

Panel Members

Francesco Negro

Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis.

Fiona Marra

Fiona Marra is Principal Pharmacist and part of the Editorial Board of the University of Liverpool, Drug Interactions websites, where she writes the content. She works clinically in Glasgow where is Lead Clinician for Paediatric Infection and Immunology network for Scotland and senior pharmacist for adult HIV/HCV. As an Independent prescriber, Fiona has treatment clinics in HCV and HIV, including paediatric and adult populations.

Olav Dalgard

Olav Dalgard is a consultant and professor at Akershus University Hospital and the University of Oslo, Norway. Dalgard`s research has focused on hepatitis C in people who inject drugs and includes clinical trials and epidemiological work; shortened interferon based treatment in genotype 2/3 infection, treatment of PWID, prevalence of HCV, natural history of HCV infection in PWID and reinfection after successful HCV treatment.

Heiner Wedemeyer

Heiner Wedemeyer is the Director of the Clinic of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. He has worked on basic and clinical aspects of hepatitis virus infections since 1996. His main interest is the immunopathogenesis of HBV, HCV, HDV and HEV infection and the development of novel immunomodulatory therapies such as therapeutic vaccines in hepatitis C. He has been principal investigator in several phase I-IV clinical trials on antivirals and immunotherapies in viral hepatitis.

Alessio Aghemo

Professor Alessio Aghemo is Professor of gastroenterology at Humanitas University in Milano Italy. He is the Head of the Division of Internal Medicine and Hepatology and Vice Chairmen of the Department of Medicine at the Humanitas Research Hospital in Milano Italy. He has contributed to the European clinical practice guidelines on the management and treatment of patients with chronic hepatitis C since 2014.

Massimo Puoti

Massimo Puoti is a specialist in Gastroenterology and in Infectious Diseases and he is the director of the Infectious Diseases Department of the AO Ospedale Niguarda Cà Granda, the largest hospital in Milan, Italy. He also served as Associate Professor of Infectious Diseases in the School of Medicine of the University of Brescia. The main fields of research of Dr. Puoti are Hepatitis Viruses and HIV infections.